Med­i­cine is shift­ing from small-mol­e­cule drugs to­ward cell and gene ther­a­pies (CGT) that ed­it, re­place, or re­pro­gram bi­ol­o­gy at its source. For Sau­di Ara­bia, lo­cal­iz­ing this class of med­i­cine is a foun­da­tion­al pil­lar of its Vi­sion 2030 and Na­tion­al Biotech­nol­o­gy Strat­e­gy. The Riyadh Glob­al Med­ical Biotech­nol­o­gy Sum­mit (RGMBS) is the pri­ma­ry fo­rum where that tran­si­tion is be­ing worked out, bring­ing reg­u­la­to­ry, in­dus­tri­al, and aca­d­e­m­ic groups to­geth­er to build a do­mes­tic biotech­nol­o­gy ecosys­tem.

In Sau­di Ara­bia, that shift is be­ing shaped di­rect­ly by the Na­tion­al Biotech­nol­o­gy Strat­e­gy, which sets the King­dom's biotech­nol­o­gy am­bi­tions through 2030 and 2040 across four pil­lars: vac­cines, bio­man­u­fac­tur­ing and lo­cal­iza­tion, ge­nomics, and plant op­ti­miza­tion. H.E. Prof. Ban­dar Alk­nawy, Chief Ex­ec­u­tive Of­fi­cer of the Min­istry of Na­tion­al Guard Health Af­fairs and Pres­i­dent of King Saud bin Ab­du­laz­iz Uni­ver­si­ty for Health Sci­ences (KSAU-HS), has point­ed to sci­en­tif­ic in­fra­struc­ture, in­clud­ing lab­o­ra­to­ries, in­te­grat­ed re­search cen­ters, and clin­i­cal tri­al net­works, and to in­vest­ment in na­tion­al tal­ent and lead­er­ship across acad­e­mia, in­dus­try, and reg­u­la­tion, as the foun­da­tions the strat­e­gy is built on. RGMBS is where those foun­da­tions are put in front of an in­ter­na­tion­al au­di­ence.

As Di­rec­tor of the Sau­di Biobank Cen­ter at the King Ab­dul­lah In­ter­na­tion­al Med­ical Re­search Cen­ter (KAIM­RC), I have watched RGMBS evolve from an emerg­ing sci­en­tif­ic gath­er­ing in­to a sum­mit that in­creas­ing­ly func­tions as a work­ing ses­sion rather than a cer­e­mo­ni­al one. For me, it has come to rep­re­sent more than a con­fer­ence: it is where ideas ma­ture in­to col­lab­o­ra­tions, col­lab­o­ra­tions be­come strate­gic part­ner­ships, and part­ner­ships trans­late in­to im­pact for pa­tients.

Lo­cal­iz­ing CGT re­quires a com­plex in­te­gra­tion of gov­ern­ment, acad­e­mia, and in­dus­try, a mod­el of­ten called the triple he­lix of in­no­va­tion. RGMBS op­er­ates as a co­or­di­na­tion plat­form that brings these groups to­geth­er and, in do­ing so, moves be­yond a tra­di­tion­al trade ex­hi­bi­tion. By con­nect­ing glob­al bio­phar­ma­ceu­ti­cal firms with lo­cal re­search in­sti­tu­tions such as KAIM­RC, the sum­mit sup­ports the trans­fer of tech­ni­cal ex­per­tise need­ed to scale com­plex man­u­fac­tur­ing process­es such as vi­ral vec­tor pro­duc­tion and au­tol­o­gous T-cell pro­cess­ing. That kind of in­sti­tu­tion­al ex­change helps en­sure the King­dom's in­fra­struc­ture de­vel­op­ment is in­formed by prac­tices al­ready es­tab­lished else­where, which low­ers the risk that comes with build­ing a biotech­nol­o­gy in­dus­try from a rel­a­tive­ly ear­ly stage.

A sig­nif­i­cant bar­ri­er to do­mes­tic gene ther­a­py pro­duc­tion is the cap­i­tal ex­pen­di­ture re­quired for cGMP-com­pli­ant fa­cil­i­ties. RGMBS serves as a venue for de-risk­ing that in­vest­ment. By giv­ing en­ti­ties such as Lif­era a plat­form to present their con­tract de­vel­op­ment and man­u­fac­tur­ing or­ga­ni­za­tion (CD­MO) ca­pa­bil­i­ties to an in­ter­na­tion­al au­di­ence, the sum­mit helps val­i­date the King­dom's readi­ness to host com­plex man­u­fac­tur­ing. The sum­mit al­so high­lights the reg­u­la­to­ry ma­tu­ri­ty the Sau­di Food and Drug Au­thor­i­ty (SF­DA) has achieved through its WHO Ma­tu­ri­ty Lev­el 4 (ML4) sta­tus. That recog­ni­tion mat­ters for for­eign di­rect in­vest­ment (FDI): it as­sures glob­al firms of a trans­par­ent, pre­dictable, and de­pend­able frame­work for the clin­i­cal and com­mer­cial ap­proval of ad­vanced ther­a­pies.

Clin­i­cal adop­tion of CGT de­pends on high-qual­i­ty clin­i­cal tri­al en­vi­ron­ments. RGMBS has be­come a venue for ex­pand­ing these net­works, fa­cil­i­tat­ing part­ner­ships that draw on Sau­di Ara­bi­a's pop­u­la­tion da­ta and high-vol­ume clin­i­cal cen­ters. By con­nect­ing glob­al drug de­vel­op­ers with lo­cal prin­ci­pal in­ves­ti­ga­tors, the sum­mit sup­ports the growth of clin­i­cal tri­al reg­istries fo­cused on rare dis­ease and on­col­o­gy. That growth is one in­di­ca­tor of the in­creas­ing ca­pac­i­ty of the Sau­di health­care sys­tem to act as a part­ner in the trans­la­tion­al re­search path­way, and it is re­flect­ed in the ris­ing num­ber of clin­i­cal re­search ap­pli­ca­tions the SF­DA has re­port­ed pro­cess­ing in re­cent years.

A knowl­edge-based econ­o­my needs a work­force that can work across bioin­for­mat­ics, ge­net­ic en­gi­neer­ing, and ad­vanced man­u­fac­tur­ing. RGMBS func­tions as an ag­gre­ga­tor that con­nects aca­d­e­m­ic out­put with in­dus­try need. Through its sci­en­tif­ic tracks and sym­posia, the sum­mit en­gages Sau­di sci­en­tists in dis­cus­sions on AI-dri­ven drug dis­cov­ery and ge­nom­ic med­i­cine, work that mat­ters be­cause phys­i­cal in­fra­struc­ture is on­ly as use­ful as the peo­ple who can run it.

Look­ing back at pre­vi­ous edi­tions, sev­er­al things stand out. The grow­ing par­tic­i­pa­tion of glob­al biotech­nol­o­gy lead­ers along­side Sau­di gov­ern­ment bod­ies, aca­d­e­m­ic in­sti­tu­tions, and health­care providers sug­gests Sau­di Ara­bia is in­creas­ing­ly seen as a part­ner in biotech­nol­o­gy in­no­va­tion rather than on­ly a health­care mar­ket. So has the grow­ing em­pha­sis on trans­la­tion­al re­search, bio­man­u­fac­tur­ing, ge­nom­ic med­i­cine, and ar­ti­fi­cial in­tel­li­gence, all cen­tral to a mod­ern ad­vanced ther­a­peu­tics ecosys­tem.

For the Sau­di Biobank, these sum­mits have been an op­por­tu­ni­ty to show how high-qual­i­ty biospec­i­mens, in­te­grat­ed clin­i­cal da­ta, and well-gov­erned re­search plat­forms can ac­cel­er­ate pre­ci­sion med­i­cine, and to have con­ver­sa­tions with in­ter­na­tion­al phar­ma­ceu­ti­cal com­pa­nies, tech­nol­o­gy providers, se­quenc­ing plat­forms, and aca­d­e­m­ic col­lab­o­ra­tors. Sev­er­al of those con­ver­sa­tions have grown in­to on­go­ing part­ner­ships. My strongest take­away from pre­vi­ous edi­tions is that ad­vanced ther­a­pies can­not suc­ceed with­out equal­ly ad­vanced na­tion­al re­search in­fra­struc­ture: high-qual­i­ty biospec­i­mens, com­pre­hen­sive ge­nom­ic datasets, lon­gi­tu­di­nal clin­i­cal in­for­ma­tion, and stan­dard­ized gov­er­nance. Biobanks are not mere­ly sup­port­ing in­fra­struc­ture. They are foun­da­tion­al as­sets that en­able bio­mark­er dis­cov­ery, pa­tient strat­i­fi­ca­tion, clin­i­cal tri­al re­cruit­ment, and ul­ti­mate­ly the lo­cal­iza­tion of pre­ci­sion med­i­cine.

This year's sum­mit comes at an ac­tive mo­ment for the sec­tor. Sau­di Ara­bia is work­ing on sev­er­al fronts at once: im­ple­ment­ing the Na­tion­al Biotech­nol­o­gy Strat­e­gy, strength­en­ing reg­u­la­to­ry ma­tu­ri­ty through the SF­DA, ex­pand­ing do­mes­tic bio­man­u­fac­tur­ing ca­pac­i­ty, and in­creas­ing in­ter­na­tion­al in­vest­ment. At the same time, the sci­en­tif­ic com­mu­ni­ty ap­pears to be con­verg­ing on a shared goal of build­ing an end-to-end biotech­nol­o­gy ecosys­tem with­in the King­dom.

What I am most look­ing for­ward to this year is dis­cus­sion of in­te­grat­ed na­tion­al ecosys­tems rather than in­di­vid­ual tech­nolo­gies: con­nect­ing biobanks, ge­nom­ic se­quenc­ing ini­tia­tives, clin­i­cal tri­al net­works, dig­i­tal health in­fra­struc­ture, ad­vanced man­u­fac­tur­ing, and reg­u­la­to­ry sci­ence in­to a sin­gle pipeline. That kind of in­te­gra­tion is what would let Sau­di Ara­bia move from adopt­ing ad­vanced ther­a­pies to de­vel­op­ing them.

If you're work­ing on any piece of this, cell and gene ther­a­py, biobank­ing, reg­u­la­to­ry sci­ence, or just want to see where the King­dom's biotech strat­e­gy is head­ing, come check out RGMBS this Sep­tem­ber. I'll be there and would love to com­pare notes. Full pro­gram's at rgmbs.org.

Eli Lil­ly is fur­ther strength­en­ing its po­si­tion in im­munol­o­gy with its 13th ac­qui­si­tion of the year, pay­ing up to $2.875 bil­lion for Meri­da Bio­sciencesand...

Biotech's IPO sum­mer is­n't over yet.

Elec­tra Ther­a­peu­tics plans to be­gin pub­lic trad­ing on the Nas­daq af­ter the La­bor Day hol­i­day, ac­cord­ing to a Fri­day...